[Skip to Content]
[Skip to Content Landing]
Article
February 24, 1989

Contrasting Effects of Testosterone and Stanozolol on Serum Lipoprotein Levels

Author Affiliations

From the Department of Medicine, The Miriam Hospital, and Brown University Program in Medicine, Providence, RI (Drs Thompson, Sady, and Herbert; Ms Cullinane; Ms Chenevert; and Ms Sady).

From the Department of Medicine, The Miriam Hospital, and Brown University Program in Medicine, Providence, RI (Drs Thompson, Sady, and Herbert; Ms Cullinane; Ms Chenevert; and Ms Sady).

JAMA. 1989;261(8):1165-1168. doi:10.1001/jama.1989.03420080085036
Abstract

Oral anabolic steroids produce striking reductions in serum concentrations of high-density lipoprotein (HDL) cholesterol. We hypothesized that this effect related to their route of administration and was unrelated to their androgenic potency. We administered oral stanozolol (6 mg/d) or supraphysiological doses of intramuscular testosterone enanthate (200 mg/wk) to 11 male weight lifters for six weeks in a crossover design. Stanozolol reduced HDL-cholesterol and the HDL2 subfraction by 33% and 71%, respectively. In contrast, testosterone decreased HDL-cholesterol concentration by only 9% and the decrease was in the HDL3 subfraction. Apolipoprotein A-I level decreased 40% during stanozolol but only 8% during testosterone treatment. The low-density lipoprotein cholesterol concentration increased 29% with stanozolol and decreased 16% with testosterone treatment. Stanozolol, moreover, increased postheparin hepatic triglyceride lipase activity by 123%, whereas the maximum change during testosterone therapy ( + 25%) was not significant. Weight gain was similar with both drugs, but testosterone was more effective in suppressing gonadotropic hormones. We conclude that the undesirable lipoprotein effects of 17-α-alkylated steroids given orally are different from those of parenteral testosterone and that the latter may be preferable in many clinical situations.

(JAMA. 1989;261:1165-1168)

×